Catalyst Pharmaceuticals, Inc. (CPRX) - Stock Analysis
Last updated: Apr 25, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Strong revenue and EPS growth with key product expansions, raised guidance, positive analyst sentiment, technical breakout above resistance, and favorable biotech sector tailwinds make it a compelling short-term growth candidate.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong liquidity ⢠Low leverage ⢠Slower quarter CPRX looks fundamentally strong with excellent liquidity, low leverage, solid margins, and robust cash flow, but recent quarterly results show some slowdown in earnings and cash generation.
Price Behavior
Key Price Behavior Insights: ⢠Higher highs ⢠Near-term fatigue ⢠Support hold Support Level: $25.60â$26.00 Resistance Level: $27.68 CPRX has been in a strong uptrend over the last month with higher highs and higher lows, but the recent pullback from $27.68 to $27.37 suggests short-term fatigue and makes $25.60â$26.00 the key support zone to hold before another leg higher.
Sentiment & News
Key News Insights: ⢠Analyst upside ⢠Price momentum ⢠Valuation caution Catalyst Pharmaceuticals (CPRX) is drawing sustained bullish attention from analysts, value screens, and price-momentum signals, though some headlines caution that near-term upside may already be partly priced in.
AI Summary
CPRX should now be viewed less as a speculative biotech and more as a cash-generating commercial platform with self-funding capacity, but the investment hinges on whether FIRDAPSE and AGAMREE can keep compounding fast enough to offset FYCOMPA erosion and justify the stock's already elevated rerating.
Description
Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company based in Coral Gables, Florida, that develops and sells therapies for rare neuromuscular and neurological disorders in the United States. Its marketed products include amifampridine formulations for adult and pediatric Lambert-Eaton myasthenic syndrome, and the company is advancing that therapy into additional neuromuscular indications such as certain forms of myasthenia gravis and spinal muscular atrophy. Catalyst also maintains licensing and collaboration arrangements with third parties, including BioMarin and Endo Ventures, and was founded in 2002 (renamed to its current corporate identity in 2015).
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Dec 17 | Dec 24 | CPRX | Catalyst Pharmaceuticals, Inc. | Strong revenue and EPS growth with key product expansions, raised guidance, positive analyst sentiment, technical breakout above resistance, and favorable biotech sector tailwinds make it a compelling short-term growth candidate. | Closed | +1.9% |